NOVARA · Novel Vaccines for Allergen-specific immunotherapy of Ragweed pollen Allergy
7РП — „Хора“ (Действия „Мария Кюри“)
- Период
- 2010-11-01 → 2012-10-31
- Финансиране от ЕС
- 218 015 €
- Участници
- 1
- Схема
- MC-IEF
Линиите свързват координатора с партньорите.
Накратко на български
Нови ваксини срещу алергията към амброзия и пелин се разработват чрез създаване на специални протеини в лаборатория. Те могат да направят имунотерапията по-безопасна, като намалят риска от тежки странични ефекти в сравнение с традиционните биологични екстракти.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
Novel Vaccines for Allergen-specific immunotherapy of Ragweed pollen Allergy
The aim of the project “Novel Vaccines for Allergen-specific immunotherapy of Ragweed pollen Allergy” is two-fold: (1) to develop the heterologous expression of hypoallergenic pectate lyases from ragweed and mugwort pollen and (2) to characterise the allergenic and immunogenic effect of these proteins for use as putative vaccine candidates for allergen-specific immunotherapy. Ragweed is considered highly allergenic since very low pollen concentrations are sufficient to trigger allergic symptoms in sensitized individuals, including hay fever, asthma, contact dermatitis and anaphylaxis. Short ragweed or common ragweed (Ambrosia artemisiifolia or Ambrosia elatior) is widespread especially across the United States, Canada and Europe, where it is particularly abundant in France, North Italy, Austria, Hungary, Croatia and Bulgaria. Amb a 1 is the major allergen of ragweed pollen which cross-reacts with Art v 6 from mugwort pollen at the IgE and T cell level. Both proteins comprises of two chains, the alpha-chain featuring all the requirements of a hypoallergenic molecule i.e. low IgE reactivity and maintained T cell reactivity, and could therefore be considered a naturally occurring hypoallergen. However, plant derived members of this family are difficult to produce in a heterologous recombinant form and consequently are not available for therapy. Therefore, clinically relevant, well defined hypoallergenic variants are needed for the development of better reagents for immunotherapy with minimised risk of anaphylactic side effects and shorter regimens compared to the variable biological extracts.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
Ragweed pollen allergy is a new and steadily growing health problem in Europe. The aim of the proposed Marie Curie Fellowship, NOVARA, is to engineer hypoallergenic Amb a 1, the major allergen of ragweed pollen, for use as new vaccine candidates for allergen-specific immunotherapy (SIT). Since conventional SIT may induce undesired IgE-mediated side-effects, there is a need for well defined proteins with reduced or abolished IgE binding capacity and retained T cell-activating capacity, as substitutes for the highly variable natural allergen extracts. Hypoallergenic variants of Amb a 1 have not yet been fully explored. In particular, it is unclear which structural modifications of hypoallergens could improve their effectiveness for use as active components in allergy therapy with minimised risk of anaphylactic side effects and shorter treatment regimens. Thus, a number of hypoallergenic variants, with different sizes and folding status, will be produced within NOVARA and the most promising candidates will be fully characterized, including the analysis of primary structure, folding, surface exposed hydrophobic portions, aggregation status and stability. Human IgE reactivity, allergenicity and T cell responses will be investigated as indicative of their immunogenicity in humans. The in vivo capacity of the candidate vaccines to induce humoral and cellular responses will be evaluated in a murine model. The opportunity to acquire additional scientific skills in molecular biology and immunology, as well as dealing with intellectual property, ethical and management issues, will allow the Applicant to reach a position of professional maturity. NOVARA has industrial and clinical interests and further strengthens the EU research portfolio in the allergy field.
Оригинален текст от CORDIS (на английски).
Участници
- PARIS-LODRON-UNIVERSITAT SALZBURG · SalzburgКоординаторАвстрия
Връзки
Данни: CORDIS, © Европейски съюз